Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | CD38 | P28907 | 9/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136105 | 0.85 | CSNK2A2 (0.41) | WNT1GSK3BDYRK1AHPGDPIM1 | |
| SCHEMBL21044498 | 0.79 | RAB9A (0.43) | MAPT | |
| SCHEMBL25136292 | 0.78 | ALDH1A1 (0.41) | DYRK1ACD38IMPDH2IMPDH1HPGD | |
| SCHEMBL28410092 | 0.74 | NPC1 (0.37) | HPGDMAPT | |
| SCHEMBL25136094 | 0.73 | RAB9A (0.40) | WNT1GSK3BDYRK1AMAPT | |
| SCHEMBL25136437 | 0.73 | SMN1; SMN2 (0.39) | MAPT | |
| SCHEMBL28410129 | 0.71 | ALDH1A1 (0.40) | MAPT | |
| SCHEMBL25136381 | 0.69 | CD38 (0.45) | CD38HPGD | |
| SCHEMBL7016486 | 0.67 | MEN1 (0.51) | HPGDMAPT | |
| SCHEMBL25136274 | 0.66 | MCL1 (0.43) | HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117813296-A | CD38 modulators and methods of use thereof | 赛特凯恩蒂克公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | WNT1 3499/4885GSK3B 395/4885DYRK1A 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.